University of Iowa Research Park

Center for Biocatalysis and Bioprocessing (CBB) is a renowned Biotechnology and Health Care startup headquartered in the United States. Established in 1847, CBB's primary focus is on Microbial Manufacturing of Protein Products. The company's Research & Process Development (RPD) Facility is equipped with state-of-the-art technologies and instruments, offering comprehensive upstream and downstream process development services. With a strict adherence to protocols, documentation, and laboratory practices, the facility ensures high-quality operations. CBB's cGMP Manufacturing Facility provides fermentation and protein purification services specifically tailored for Phase-1 clinical trials. They offer a wide range of microbial protein product production services, including strain development and large-scale manufacturing, in accordance with the 2008 FDA guidance for cGMP manufacturing of materials for Phase-1 investigational drugs. The company's services include Upstream Process Development, covering aspects such as cloning, fermentation optimization, scale-up, and BSL-1 microbial expression systems. Additionally, CBB provides Downstream Process Development services, leveraging advanced techniques like ÄKTA purification systems, homogenization-extraction, and multiple chromatography techniques. In terms of cGMP Manufacturing Services for Phase-1 clinical trials, CBB offers cell banking, fermentation, and protein purification within ISO7 clean rooms. It also extends its services to include Fill-Finish Services, in collaboration with The University of Iowa, and supports Clinical Trials. Although the specific details of the last investment and investors are currently unavailable, CBB's comprehensive facilities and services set it apart as a promising player in the biotechnology and healthcare industries. Its expertise in microbial manufacturing and commitment to quality make it a noteworthy prospect for potential venture capital investments.